Answers are grounded in this paper and cite their sources.
To help save lives and improve human health, it is crucial for policy makers to ensure equity in access to drugs, drug efficacy, quality and safety, and rational use of drugs, which are indicators of the National Drug Policy (NDP) in evaluation of pharmaceutical system performance in every country. There are some retrospective evaluation methods that are currently used to appraise the success of NDP and adherence to its objectives in the relevant countries. They found that although the system, structures, and mechanisms are in place, they do not function properly in some topics. Assessment of 59 dossiers of approved drugs for adding to the NDL during a 5-year period showed that decision makers pay more attention to efficacy, safety, and rationality in use rather than accessibility and affordability. Our belief is that the problem is still there and has not been resolved yet by the national drug authority (NDA) and the objectives of national drug policies (NDP) have not been met yet
No takes yet. Share an insight, caveat, or question.
Abdollahiasl et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: